Sinclair Pharma PLC’s (SPH) “Buy” Rating Reiterated at N+1 Singer
N+1 Singer restated their buy rating on shares of Sinclair Pharma PLC (LON:SPH) in a research report sent to investors on Tuesday morning, Marketbeat.com reports. They currently have a GBX 37 ($0.50) price objective on the specialty pharmaceutical company’s stock.
Several other analysts have also commented on SPH. Peel Hunt reissued a buy rating and set a GBX 68 ($0.92) price target on shares of Sinclair Pharma PLC in a research report on Tuesday. Stifel Nicolaus reissued a buy rating and set a GBX 71 ($0.96) price target on shares of Sinclair Pharma PLC in a research report on Tuesday, July 11th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Sinclair Pharma PLC has an average rating of Buy and an average target price of GBX 54 ($0.73).
Sinclair Pharma PLC (LON SPH) opened at 27.00 on Tuesday. Sinclair Pharma PLC has a one year low of GBX 26.00 and a one year high of GBX 36.35. The stock’s market capitalization is GBX 135.59 million. The firm has a 50-day moving average of GBX 29.00 and a 200 day moving average of GBX 31.10.
About Sinclair Pharma PLC
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.